• Home
  •  / Karo Pharma

Karo Pharma

OverviewSuggest Edit

Karo Pharma is a healthcare company, which develops and markets products for pharmacies and the health care sectors. The Company's development projects are focused on nuclear receptors as target proteins for the development of pharmaceuticals. Its products include medical compression socks, nutritional products, ergonomic products for people with disabilities, and medicine storage products. The Company also offers medicines for the treatment of sore throats, vaginal dryness, pains, etc. Its products under development include nuclear receptor RORgamma based products for the treatment of autoimmune diseases, compounds to treat multiple sclerosis and cancer, and a common cold spray.

TypePublic
Founded1987
HQStockholm, SEMap
Websitekaropharma.com

Recent NewsAll News

Latest Updates

Employees (est.) (Jul 2021)192
Share Price (Nov 2021)KR58.5(+2%)
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Karo Pharma

Christoffer Lorenzen

Christoffer Lorenzen

Chief Executive Officer
Jon Johnsson

Jon Johnsson

Chief Financial Officer
Carl Lindgren

Carl Lindgren

Vice President Business Development
Jonathan Kimber

Jonathan Kimber

VP Operations
Sofia Pedersen

Sofia Pedersen

VP Scientific Affairs
Lisa Westerdahl

Lisa Westerdahl

VP Commercial Pharma Operations & Corporate Communications
Show more

Karo Pharma Office Locations

Karo Pharma has an office in Stockholm
Stockholm, SE (HQ)
Klara Norra kyrkogata 33
Show all (2)

Karo Pharma Financials and Metrics

Karo Pharma Revenue

Market capitalization (10-Nov-2021)

13.2b

Closing stock price (10-Nov-2021)

58.5
Karo Pharma's current market capitalization is kr13.2 b.
Show all financial metrics

Karo Pharma Cybersecurity Score

Cybersecurity ratingPremium dataset

C

78/100

Learn more about our premium products
SecurityScorecard logo

Karo Pharma Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

Karo Pharma Online and Social Media Presence

Karo Pharma's Trends

Embed Graph

Karo Pharma News and Updates

November 27, 2019

Karo Pharma divests Hydrokortison Trimb to Evolan Pharma

As previously communicated, Karo Pharma Aktiebolag (“Karo Pharma”) voluntarily and within a certain time undertook to divest Hydrokortison Trimb and all intellectual property rights and assets relating thereto, including necessary licenses and permits as well as existing stock, to an external buyer …
June 25, 2019

Karo Pharma buys Swedish consumer healthcare firm Trimb

Karo Pharma AB has acquired Trimb, a Swedish consumer healthcare company, for about $366 million. The deal is expected to close before the end of the year. Trimb was backed by Avista Capital Partners.
June 25, 2019

Avista Capital Partners To Sell Trimb To Karo Pharma

NEW YORK and STOCKHOLM, June 25, 2019 /PRNewswire/ -- Avista Capital Partners ("Avista"), a leading private equity firm focused on growth-oriented healthcare businesses, today announced that Karo Pharma AB (publ) (the "Company" or "Karo Pharma"), a specialty pharma company, has acquired...
April 09, 2019

Karo Pharma publishes the 2018 annual report

Today, on 9 April 2019, Karo Pharma is publishing its annual report for 2018 on the company’s website, www.karopharma.com (http://%20www.karopharma.com).read more

Karo Pharma Blogs

November 22, 2021

Karo Pharma acquires Sylphar International NV for EUR 290m and intends to carry out a rights issue of approximately EUR 200-250m

Karo Pharma Aktiebolag (publ) (the ”Company” or ”Karo”) has today entered into an agreement to acquire all of the shares in Sylphar International NV (“Sylphar”) and, direct and indirect, all of the shares in Pro Teeth Whitening Co Limited (“Pro Teeth Whitening”), Nutravita Limited (“Nutravita”) and …
October 28, 2021

Karo Pharma Quarterly report Q3 2021

July – September Revenues amounted to MSEK 738.5 (679.1), corresponding to an increase of +9% for the period. The organic growth1 during the third quarter was +13%. The currency impact in the quarter was 0% while the divestments generated an effect of -4%. EBIT (Operating Profit) amounted to MSEK 99…
September 07, 2021

Anna Hale appointed CMO at Karo Pharma

Karo Pharma Aktiebolag (publ) (“Karo”) has appointed Anna Hale as the Chief Marketing Officer (CMO) of Karo. The appointment reflects Karo’s growth ambitions, fueled by a strategy of geographical expansion and development of its portfolio of consumer healthcare brands, plus the continuous efforts to…
August 24, 2021

Magnus Nylén leaves Karo Pharma, Matt Roberts appointed new CCO

Karo Pharma Aktiebolag (“Karo”) has appointed Matt Roberts as the new Chief Commercial Officer (CCO) of Karo, replacing Magnus Nylén who has decided to pursue opportunities outside of Karo. Matt will start his new position on September 1, 2021. “I would like to thank Magnus for his contributions at …
July 22, 2021

Interim report Q2 2021

April – June Revenues amounted to MSEK 747.9 (688.9), corresponding to an increase of +9% for the period. The organic growth1 during the second quarter was +8%. The currency impact in the quarter was 0% while the acquisitions of the product portfolios Pevaryl® from Johnson & Johnson and Flux®, D…
July 01, 2021

Karo Pharma divests brand portfolio to Evolan Pharma

Karo Pharma AB (“Karo”) today announces the divestment of a portfolio consisting of 12 brands to Evolan Pharma AB (“Evolan”). The transaction is effective per today, July 1[st], 2021. Inlägget Karo Pharma divests brand portfolio to Evolan Pharma dök först upp på Karo Pharma.
Show more

 Karo Pharma Frequently Asked Questions

  • When was Karo Pharma founded?

    Karo Pharma was founded in 1987.

  • Who are Karo Pharma key executives?

    Karo Pharma's key executives are Christoffer Lorenzen, Jon Johnsson and Carl Lindgren.

  • How many employees does Karo Pharma have?

    Karo Pharma has 192 employees.

  • Who are Karo Pharma competitors?

    Competitors of Karo Pharma include Enzymatica, LianBio and RAPT Therapeutics.

  • Where is Karo Pharma headquarters?

    Karo Pharma headquarters is located at Klara Norra kyrkogata 33, Stockholm.

  • Where are Karo Pharma offices?

    Karo Pharma has an office in Stockholm.

  • How many offices does Karo Pharma have?

    Karo Pharma has 2 offices.